Reply to Blom: Drugs Do Not Work in Patients Who Cannot Tolerate Them-Reference-Cited by-同舟云学术

Reply to Blom: Drugs Do Not Work in Patients Who Cannot Tolerate Them

Published:2024-08-01 Issue:3 Volume:7 Page:96-97
ISSN:2589-9449
Container-title:Global Journal on Quality and Safety in Healthcare
language:en
Short-container-title:

Author:

Esba Laila Carolina Abu¹²³^ORCID,Alharbi Hani⁴

Affiliation:

1. 1 Pharmaceutical Care Department, King Abdulaziz Medical City, Ministry of National Guard, Health Affairs, Riyadh, Saudi Arabia

2. 2 King Saud Bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia

3. 3 King Abdullah International Medical Research Centre, Riyadh, Saudi Arabia

4. 4 Pharmaceutical Care Department, King Fahd Hospital, University of Immam Abulrahman Bin Faisal, Dammam, Saudi Arabia

Publisher

Innovative Healthcare Institute

Link

https://meridian.allenpress.com/innovationsjournals-JQSH/article-pdf/7/3/96/3413670/i2589-9449-7-3-96.pdf

Reference8 articles.

1. Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study;Cuchel;Lancet,2013

2. Letter in response to “Lomitapide: a medication use evaluation and a formulary perspective” by Esba and Alharbi;Blom;Glob J Qual Saf Healthc,2024

3. Lomitapide: a medication use evaluation and a formulary perspective;Esba;Glob J Qual Saf Healthc,2024

4. Danawi, H. Where are all the Arabs? and how a U.S. census change could improve clinical trial diversity. Clinical Leader. Aug 25, 2023. Accessed May 2, 2024. www.clinicalleader.com/doc/where-are-all-the-arabs-and-how-a-u-s-census-change-could-improve-clinical-trial-diversity-0001

5. The Health Sector Transformation Program. Vision 2030. Accessed May 2, 2024. www.vision2030.gov.sa/en/vision-2030/vrp/health-sector-transformation-program/